newsfilter
← Latest News
GlobeNewswire·

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year